Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...
Yahoo Finance9d
Eupraxia reports positive data from eosinophilic esophagitis treatment trial
The Eosinophilic Esophagitis Histology Scoring System (EoEHSS ... aligning with US Food and Drug Administration guidance for ...
unr.edu3d
Meet a UNR Med Scientist – Caroline Cobine, Ph.D.
Caroline Cobine, Ph.D., an associate professor in the Department of Physiology and Cell Biology within the University of ...
T-Net2d
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...
Pharmaceutical Technology12d
CALY-002 by Novartis for Eosinophilic Esophagitis: Likelihood of Approval
CALY-002 is under development for the treatment of eosinophilic esophagitis, celiac disease and unspecified dermatological disorders. It is a fully-humanized monoclonal antibody also administered ...
WTKR10d
How cancer patients can get free rides to treatment
A special program organized by the American Cancer Society helps cancer patients get to their treatments for free ...
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...
Nasdaq10d
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis ("EoE"). New Clinical Data from the Fourth Cohort of the RESOLVE Trial The results announced ...
Sanofi: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...